Antibiotic Development Hinges On Financial Incentives, Experts Tell Congress
This article was originally published in The Pink Sheet Daily
FDA’s Janet Woodcock supports streamlining approval of antibiotics but says it won’t solve problem of industry investment; others point to BARDA as model for government funding.
You may also be interested in...
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.